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evaluation of toll-like receptors as 
prognostic biomarkers in gastric 
cancer: high tissue TLR5 predicts a 
better outcome
Aaro Kasurinen  1, Jaana Hagström2, Alli Laitinen1,3, Arto Kokkola3, camilla Böckelman1,3 & 
caj Haglund1,3
Toll-like receptors (TLRs), key proteins in innate immunity, appear to contribute to the inflammatory 
environment in carcinogenesis. Thus, we aimed to evaluate the tissue expressions of TLR1, 
TLR2, TLR4, TLR5, TLR7, and TLR9 as potential prognostic biomarkers in gastric cancer. We 
applied immunohistochemistry to study tissue samples from 313 patients operated on for gastric 
adenocarcinoma between 2000 and 2009 at the Department of Surgery, Helsinki University Hospital, 
Finland. A high expression of each TLR studied associated with the high expression of each other and 
with the intestinal-type histology (p < 0.001 for all). Five-year disease-specific survival among patients 
with a high TLR5 was 53.4% (95% confidence interval [CI] 43.4–63.4), whereas among patients with a 
low TLR5 it was 37.6% (95% CI 30.0–45.2; p = 0.014). A high TLR5 expression functioned as a marker of 
a better prognosis, particularly among those with a stage II disease (hazard ratio [HR] 0.33; 0.13–0.83; 
p = 0.019) or an intestinal-type cancer (HR 0.58; 95% CI 0.34–0.98; p = 0.043). In this study we show, 
for the first time, that a high TLR5 tissue expression may identify gastric cancer patients with a better 
prognosis, particularly among those with a stage II disease or an intestinal-type cancer.
Gastrointestinal tract malignancies cause more cancer-related deaths worldwide than any other form of can-
cer, accounting for more than 20% of all cancer-related fatalities1. Late diagnosis, often occurring already at an 
advanced disease stage, and a high recurrence risk result in poor prognoses.
Chronic inflammation contributes to carcinogenesis in the gastrointestinal tract, and several biomarkers have 
been studied in attempts to further clarify the pathology behind inflammation-associated cancers, including the 
toll-like receptors (TLRs)2–4. TLRs, a family of transmembranous pattern recognition receptors, play a crucial role 
in innate immunity. These receptors are expressed on antigen-presenting cells in the first line of defence, such 
as on the macrophages and dendritic cells, and activated by pathogen-associated molecular patterns5. In can-
cer, TLRs contribute to the inflammatory environment via activation by damage-associated molecular patterns6. 
However, TLRs may assume a heterogeneous role in cancer biology, since they appear to both induce antitumour 
factors and in different contexts promote procancerous mechanisms7. A sequence of increasing TLR2, TLR4, and 
TLR5 expression levels was observed with progression from normal gastric mucosa to pre-cancerous lesions, 
gastric dysplasia, and ultimately to gastric adenocarcinoma8. The highest TLR expression levels were found in 
dysplastic lesions, suggesting that TLRs may play a specific role in gastric cancer development.
TLR4 represents the most widely studied TLR in gastric cancer, and its polymorphism may associate with an 
increased risk of gastric cancer9,10. Furthermore, TLR4 signalling activation in gastric cancer cells by lipopolysac-
charides increase the risk of metastasis11. In a study among 106 gastric adenocarcinoma patients, TLR3, TLR4, 
and TLR9 were highly expressed in gastric cancer tissues and survival worsened among patients with a high TLR3 
expression12. Moreover, TLR2 expression in gastric cancer has been linked to metastatic disease and increased 
invasion13. In addition, TLR5 activation by flagellin, the major structural protein in bacterial flagellum, increases 
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the proliferation of gastric cancer cells14. Subsequent TLR5 antagonism appeared to cancel the effect, suggesting 
that TLR5 signalling clearly contributes to the proliferation of gastric cancer cells. Yet, administering imiquimod 
(a TLR7 agonist) to gastric cancer cells results in a reduced proliferation15. In that study, TLR7 expression was 
low in gastric cancer cells compared to levels in adjacent healthy tissue. Genetic variations of TLR1 combined 
with an Helicobacter Pylori (H. pylori) infection predispose an individual to develop gastric cancer16. However, 
TLR1 remains unstudied using immunohistochemistry. TLRs are promising biomarkers, yet due to their diverse 
functions, further research is needed to clarify their roles in gastric cancer.
Therefore, in this study, we aimed to explore the tissue expression of TLR1, TLR2, TLR4, TLR5, TLR7, and 
TLR9 as potential prognostic biomarkers in gastric cancer patients, and to examine their associations with several 
clinicopathological variables.
Methods
patients. We retrospectively studied 313 patients operated on for gastric cancer between 2000 and 2009 in 
the Department of Surgery, Helsinki University Hospital. Each gastric tumour was histologically confirmed as 
gastric adenocarcinoma by a pathologist of the Helsinki University Hospital. Individuals undergoing surgery were 
consecutively included in our patient cohort; we excluded patients with a history of malignant disease or any syn-
chronous cancers. The median age at the time of surgery was 67.4 years (interquartile range [IQR] 57.1–76.5) and 
152 (48.6%) were male. The median follow-up time was 2.3 years, with 66 (21.1%) patients alive at the end of fol-
low-up. Living data until September 2017 were obtained from patient records, the Population Register Centre of 
Finland, and Statistics Finland. The five-year disease-specific survival for all patients was 43.3% (95% confidence 
interval [CI] 37.4–49.2). We used the seventh version of the TNM classification for disease staging17.
The Surgical Ethics Committee of Helsinki University Hospital approved our study (Dnro HUS 226/E6/ 06, 
extension TMK02 §66 17 April 2013). Permission to study archived tissue samples without individual consent was 
granted by the National Supervisory Authority of Welfare and Health (Valvira Dnro 10041/06.01.03.01/2012).
Tissue samples and immunohistochemistry. We applied the same immunohistochemical staining pro-
tocol to each TLR. A tissue microarrayer (TMA Grand Master, 3D Histech Ltd, Budapest, Hungary) was used to 
Figure 1. Representative images of immunohistochemistry demonstrating gastric cancer tumours with low 
versus high TLR immunoreactivities. Original magnification was 20×.
Immunoreactivity
Strong (%) Moderate (%) Weak (%) Absent (%) Total
TLR1 29 (10.3) 115 (40.8) 120 (42.6) 18 (6.4) 282
TLR2 44 (16.0) 122 (44.4) 90 (32.7) 19 (6.9) 275
TLR4 74 (26.3) 106 (37.7) 77 (27.4) 24 (8.5) 281
TLR5 11 (4.0) 98 (35.4) 114 (41.2) 54 (19.5) 277
TLR7 30 (11.2) 95 (35.4) 108 (40.3) 35 (13.1) 268
TLR9 13 (4.7) 130 (46.9) 115 (41.5) 19 (6.9) 277
Table 1. Distribution of immunoreactivity for TLR1, TLR2, TLR4, TLR5, TLR7, and TLR9. Abbreviations: 
TLR = Toll-like receptor.
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punch four 1.0-mm cores from each sample, embedding them in a recipient block of paraffin. The TMA samples 
were subsequently cut in 4-µm sections for the immunohistochemical staining, resulting in four 1.0-mm tissue 
microarray spots per patient. The slides were deparaffined, pre-warmed in a PT module (LabVision UK Ltd, UK) 
to 65 °C, and treated for 20 min in 98 °C for antigen retrieval (Tris-EDTA buffer; pH 9.0 or Tris-Hcl buffer; pH 
8.5). The staining was performed in an Autostainer 480 (LabVision) with the Dako detection system (Dako REAL 
EnVision Detection System, Peroxidase/DAB+, Rabbit/Mouse [Dako, Glostrup, Denmark]). Endogenous per-
oxidases were blocked with the 0.3% Dako REAL Peroxidase-Blocking Solution. The slides were then incubated 
with the primary antibody, using the following primary antibodies: TLR1 rabbit polyclonal 200 µg/ml (1:100, 
1 hr, sc-30000, Santa Cruz Biotechnology, Dallas, TX, USA), TLR2 rabbit polyclonal 200 µg/ml (1:200, over-night 
(O/N), sc-10739, Santa Cruz Biotechnology), TLR4 mouse monoclonal IgG1 200 µg/ml (1:2000, 1 hr, sc-293072, 
Santa Cruz Biotechnology), TLR5 mouse monoclonal 0.1 mg/ml (1:100, 1 hr, NBP2-24787, Novus Biologicals, 
Centennial, CO, USA), TLR7 rabbit polyclonal 1.0 µg/ml (1:500, 1 hr, NBP2-24906, Novus Biologicals), and 
TLR9 mouse monoclonal 100 µg/ml (1:300, O/N, sc-52966, Santa Cruz Biotechnology). Finally, the samples were 
incubated with the peroxidase-conjugated Dako REAL EnVision/HRP, Rabbit/Mouse (ENV) secondary anti-
body for 30 min, visualised using the Dako REAL DAB+ Chromogen (10 min), and counterstained with Meyer’s 
hematoxylin.
Scoring of immunoreactivities. We scored TLR1 immunoreactivity on 282 tissue cores, TLR2 on 275 
cores, TLR4 on 281 cores, TLR5 on 277 cores, TLR7 on 268 cores, and TLR9 on 277 cores. We excluded cores 
lacking cancer tissue. Among all TLRs, reactivity was observed both in the nuclei and in the cytoplasm. We quan-
tified TLR expression by scoring the cancer cells’ cytoplasmic staining intensity. A score of 3 indicated strong 
staining, 2 moderate, 1 weak, and 0 signified the absence of staining. A total of four tissue cores per tumour 
sample were evaluated, from which we selected the tumour core with the highest score to represent each patient 
in the statistical analyses. For the final analyses, data were divided into two categories: high expression (strong 
or moderate immunoreactivity) and low expression (weak or no immunoreactivity) groups (Fig. 1). All tissue 
microarray cores were scored by two independent researchers, including an experienced pathologist from the 
Department of Pathology and Oral Pathology at the University of Helsinki (Aa.K. and J.H.), both blinded to the 
clinical data. Tissue core scores with any difference between researchers were re-evaluated, and the final score was 
reached through discussion and consensus.
TLR1 TLR2 TLR4
Low (%) High (%) p valuea Low (%) High (%) p valuea Low (%) High (%) p valuea
Age, years
   <67 76 (54.3) 64 (45.7) 0.074 61 (44.9) 75 (55.1) 0.080 55 (39.3) 85 (60.7) 0.245
   ≥67 62 (43.7) 80 (56.3) 48 (34.5) 91 (65.5) 46 (32.6) 95 (67.4)
Gender
   Male 65 (47.4) 72 (52.6) 0.626 50 (36.8) 86 (63.2) 0.336 51 (37.2) 86 (62.8) 0.662
   Female 73 (50.3) 72 (49.7) 59 (42.4) 80 (57.6) 50 (34.7) 94 (65.3)
Stage
   I 22 (40.7) 32 (59.3) 0.230 24 (48.0) 26 (52.0) 0.576 24 (44.4) 30 (55.6) 0.119
   II 30 (46.2) 35 (53.8) 23 (35.4) 42 (64.6) 17 (26.2) 48 (73.8)
   III 59 (56.7) 45 (43.3) 40 (39.2) 62 (60.8) 35 (34.0) 68 (66.0)
   IV 27 (46.6) 31 (53.4) 22 (38.6) 35 (61.4) 25 (43.1) 33 (56.9)
Tumour classification (pT)
   pT1 19 (45.2) 23 (54.8) 0.912 23 (57.5) 17 (42.5) 0.043 21 (50.0) 21 (50.0) 0.049
   pT2 20 (47.6) 22 (52.4) 11 (27.5) 29 (72.5) 13 (31.0) 29 (69.0)
   pT3 42 (48.3) 45 (51.7) 31 (36.5) 54 (63.5) 23 (26.7) 63 (73.3)
   pT4 57 (51.4) 54 (48.6) 44 (40.0) 66 (60.0) 44 (39.6) 67 (60.4)
Lymph node metastasis (pN)
   pN0 40 (43.5) 52 (56.5) 0.251 38 (43.2) 50 (56.8) 0.415 33 (35.9) 59 (64.1) 0.745
   pN1–3 92 (50.8) 89 (49.2) 68 (38.0) 111 (62.0) 61 (33.9) 119 (66.1)
Distant metastasis (pM)
   pM0 111 (49.6) 113 (50.4) 0.648 87 (39.9) 131 (60.1) 0.857 76 (34.1) 147 (65.9) 0.202
   pM1 27 (46.6) 31 (53.4) 22 (38.6) 35 (61.4) 25 (43.1) 33 (56.9)
Laurén classification
   Intestinal 37 (32.7) 76 (67.3) <0.001 21 (18.6) 92 (81.4) <0.001 22 (19.5) 91 (80.5) <0.001
   Diffuse 101 (59.8) 68 (40.2) 88 (54.3) 74 (45.7) 79 (47.0) 89 (53.0)
Table 2. Association of TLR1, TLR2, and TLR4 expressions with clinicopathologic variables in 313 gastric 
cancer patients. Abbreviations: TLR = Toll-like receptor. aPearson’s Chi–squared test.
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Statistical analyses. Associations and correlations were evaluated using the Pearson’s chi-squared test and 
the Spearman’s rank correlation test. We created the survival curves using the Kaplan–Meier method and com-
pared them using the log-rank test. Disease-specific survival was determined from the date of surgery until death 
from gastric cancer or until the end of the follow-up period. We applied the Cox proportional hazard model to 
calculate the hazard ratios for the uni- and multivariate survival analyses. For the multivariate survival analysis, 
we included age, stage, the Laurén classification, and TLR5 expression in our model. Stage was processed as a 
categorical covariate, and we found no significant interaction terms. For all analyses, we considered a two tailed 
p < 0.05 as statistically significant, and for all statistical analyses we used IBM SPSS Statistics version 24.0 for Mac 
(IBM Corporation, Armonk, NY, USA).
Results
Associations between TLR expression and clinicopathological variables. Table 1 summarises the 
distribution of immunoreactivities. A high TLR2 and a high TLR4 expression associated with pT2–4 tumours 
(p = 0.043; p = 0.049; Table 2), and a high TLR7 expression associated with pT3 tumours (p = 0.025; Table 3). In 
addition, a high TLR7 expression associated with stage II disease (p = 0.030) and with being male (p = 0.021). 
A high TLR5 and a high TLR9 expression associated with an older age (p = 0.028; p = 0.001). Furthermore, a 
high expression of each TLR studied associated with the intestinal-type cancer (p < 0.001 for all). Lastly, a high 
TLR5 TLR7 TLR9
Low (%) High (%) p valuea Low (%) High (%) p valuea Low (%) High (%) p valuea
Age, years
   <67 92 (67.2) 45 (32.8) 0.028 74 (56.5) 57 (43.5) 0.315 80 (58.0) 58 (42.0) 0.001
   ≥67 76 (54.3) 64 (45.7) 69 (50.4) 68 (49.6) 54 (38.8) 85 (61.2)
Gender
   Male 75 (56.0) 59 (44.0) 0.123 61 (46.2) 71 (53.8) 0.021 60 (44.4) 75 (55.6) 0.202
   Female 93 (65.0) 50 (35.0) 82 (60.3) 54 (39.7) 74 (52.1) 68 (47.9)
Stage
   I 29 (54.7) 24 (45.3) 0.255 35 (71.4) 14 (28.6) 0.030 24 (46.2) 28 (53.8) 0.961
   II 36 (55.4) 29 (44.6) 28 (43.8) 36 (56.3) 31 (47.7) 34 (52.3)
   III 64 (62.1) 39 (37.9) 53 (52.5) 48 (47.5) 52 (50.5) 51 (49.5)
   IV 39 (70.9) 16 (29.1) 27 (50.9) 26 (49.1) 27 (48.2) 29 (51.8)
Tumour classification (pT)
   pT1 22 (52.4) 20 (47.6) 0.616 28 (73.7) 10 (26.3) 0.025 20 (48.8) 21 (51.2) 0.260
   pT2 24 (60.0) 16 (40.0) 20 (51.3) 19 (48.7) 14 (34.1) 27 (65.9)
   pT3 52 (60.5) 34 (39.5) 37 (44.0) 47 (56.0) 43 (50.6) 42 (49.4)
   pT4 70 (64.2) 39 (35.8) 58 (54.2) 49 (45.8) 57 (51.8) 53 (48.2)
Lymph node metastasis (pN)
   pN0 48 (53.3) 42 (46.7) 0.090 49 (56.3) 38 (43.7) 0.483 45 (50.0) 45 (50.0) 0.634
   pN1–3 114 (64.0) 64 (36.0) 90 (51.7) 84 (48.3) 84 (46.9) 95 (53.1)
Distant metastasis (pM)
   pM0 129 (58.1) 93 (41.9) 0.082 116 (54.0) 99 (46.0) 0.694 107 (48.4) 114 (51.6) 0.978
   pM1 39 (70.9) 16 (29.1) 27 (50.9) 26 (49.1) 27 (48.2) 29 (51.8)
Laurén classification
   Intestinal 49 (43.4) 64 (56.6) <0.001 33 (29.7) 78 (70.3) <0.001 26 (23.2) 86 (76.8) <0.001
   Diffuse 119 (72.6) 45 (27.4) 110 (70.1) 47 (29.9) 108 (65.5) 57 (34.5)
Table 3. Association of TLR5, TLR7, and TLR9 expressions with clinicopathologic variables in 313 gastric 
cancer patients. Abbreviations: TLR = Toll-like receptor. aPearson’s Chi–squared test.
TLR1 TLR2 TLR4 TLR5 TLR7
rs p value rs p value rs p value rs p value rs p value
TLR2 0.314 <0.001
TLR4 0.293 <0.001 0.436 <0.001
TLR5 0.345 <0.001 0.272 <0.001 0.212 <0.001
TLR7 0.296 <0.001 0.401 <0.001 0.332 <0.001 0.253 <0.001
TLR9 0.422 <0.001 0.384 <0.001 0.361 <0.001 0.267 <0.001 0.338 <0.001
Table 4. Correlation of TLR1, TLR2, TLR4, TLR5, TLR7, and TLR9 expressions among each other in 313 
gastric cancer patients. Abbreviations: TLR = Toll-like receptor, rs = Spearman’s rank correlation coefficient.
5Scientific RepoRtS |         (2019) 9:12553  | https://doi.org/10.1038/s41598-019-49111-2
www.nature.com/scientificreportswww.nature.com/scientificreports/
expression of each TLR studied associated with high expressions of all other TLRs, whilst comparisons also 
revealed weak to moderate positive correlations (p < 0.001 for all; Table 4 and Supplementary Table 1).
Survival analyses. The five-year disease-specific survival amongst gastric cancer patients with a high TLR5 
expression was 53.4% (95% CI 43.4–63.4), compared to 37.6% (95% CI 30.0–45.2) among those with a low TLR5 
expression (p = 0.014; Table 5 and Fig. 2D). TLR1, TLR2, TLR4, TLR7, and TLR9 expressions did not function as 
significant prognostic biomarkers across the entire cohort (Fig. 2). In the multivariate survival analysis, significant 
prognostic factors consisted of age, stage, and the Laurén classification (Table 5).
In the subgroup analyses, a high TLR5 expression emerged as an indicator of a better prognosis amongst 
patients with stage II disease (hazard ratio [HR] 0.33; 95% CI 0.13–0.83; p = 0.019; Fig. 3A), amongst younger 
patients (HR 0.55; 95% CI 0.32–0.95; p = 0.033), amongst those with no distant metastasis (HR 0.66; 95% CI 
0.44–0.99; p = 0.044), and amongst those with an intestinal-type cancer (HR 0.58; 95% CI 0.34–0.98; p = 0.043: 
Fig. 3B), but not amongst those with a diffuse-type cancer (HR 0.83; 95% CI 0.53–1.31; p = 0.417; Table 6 and 
Fig. 3C). Amongst patients with a high TLR7 expression and stage I disease, no deaths due to gastric cancer were 
recorded during our follow-up period (HR 0.03; 95% CI 0.01–97.7; p = 0.392; Fig. 3D). Moreover, a high TLR7 
expression indicated a better prognosis amongst patients with stage III disease (HR 0.60; 95% CI 0.38–0.95; 
p = 0.029; Fig. 3E), amongst those with a pT4 tumour (HR 0.51; 95% CI 0.32–0.80, p = 0.003), and amongst those 
with lymph-node metastasis (HR 0.67; 95% CI 0.47–0.96; p = 0.029). Furthermore, a high TLR9 expression indi-
cated a better prognosis amongst patients with stage II disease (HR 0.30; 95% CI 0.12–0.76; p = 0.011; Fig. 3F). 
Lastly, TLR1, TLR2, and TLR4 expression levels did not significantly predict the outcome in any patient subgroup 
(Supplementary Table 2).
Discussion
In this study, we show for the first time that a high TLR5 tissue expression may identify gastric cancer patients 
with a favourable outcome, particularly amongst those with stage II disease, an intestinal-type cancer, with-
out distant metastases or a younger age. In addition to TLR5, TLR1, TLR2, TLR4, TLR7, and TLR9 were also 
expressed in gastric cancer tissues, yet their expression levels did not function as prognostic biomarkers across 
Univariate Multivariate
HR 95% CI p value HR 95% CI p value
Age, years
   <67 1.00 1.00
   ≥67 1.33 1.00–1.79 0.054 2.60 1.85–3.66 <0.001
Stage
   I 1.00 1.00
   II 5.44 2.25–13.1 <0.001 4.86 1.85–12.8 0.001
   III 15.7 6.85–36.1 <0.001 17.3 6.99–43.0 <0.001
   IV 46.2 19.6–109 <0.001 63.2 24.5–163 <0.001
Laurén classification
   Intestinal 1.00 1.00
   Diffuse 1.45 1.06–1.98 0.020 1.53 1.09–2.17 0.016
TLR1
   Low 1.00
   High 0.83 0.61–1.13 0.225
TLR2
   Low 1.00
   High 0.96 0.70–1.31 0.774
TLR4
   Low 1.00
   High 0.80 0.59–1.10 0.166
TLR5
   Low 1.00 1.00
   High 0.66 0.47–0.92 0.014 0.73 0.52–1.05 0.086
TLR7
   Low 1.00
   High 0.90 0.66–1.24 0.521
TLR9
   Low 1.00
   High 0.85 0.62–1.16 0.298
Table 5. Uni- and multivariate survival analyses for 313 gastric cancer patients. Abbreviations: TLR = Toll-like 
receptor, CI = Confidence interval, HR = Hazard ratio.
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the entire patient cohort. Furthermore, we showed that a high TLR7 expression may identify patients with a better 
prognosis amongst those with an advanced disease. High expressions of each of TLR studied associated with an 
intestinal-type cancer, suggesting that the inflammatory activity in the gastric mucosa is stronger in intestinal- 
than in diffuse-type tumours. Moreover, the high expressions of each TLR studied also associated with high 
expressions of all other TLRs.
In comparison to our results, Park et al.14 found that TLR5 activation via flagellin enhanced the proliferation 
of gastric cancer cells in vitro. Our results differ through the application of immunohistochemistry on surgical 
patient samples, where we show that the prognosis amongst gastric cancer patients with a high TLR5 expression 
is better than amongst those with a low tumour tissue expression. This discrepancy may result from the fact that 
Park et al. completed in vitro studies, whereas we conducted an in vivo study, rending the results not directly 
comparable.
TLR3, TLR4, and TLR9 were previously studied in a smaller gastric cancer patient series using a methodology 
similar to ours, relying on immunohistochemistry and tissue microarrays12. Similar to our findings, that study 
Figure 2. Gastric cancer patients’ disease-specific survival according to the Kaplan–Meier method, with p 
values for significance based on the log-rank test. High (A) TLR1, (B) TLR2, (C) TLR4, (D) TLR5, (E) TLR7, 
and (F) TLR9 expressions compared to low expressions.
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concluded that TLR4 and TLR9 expression levels did not significantly predict outcome in gastric cancer patients. 
Interestingly, in that study, a high TLR3 expression appeared to associate with a poor prognosis. Unfortunately, 
TLR3 was not included in our panel of biomarkers. In another study amongst 47 gastric cancer samples studied 
using immunohistochemistry, a high TLR2 expression associated with metastatic disease13. We found that a high 
TLR2 expression associated with an intestinal-type cancer, but not with any other clinicopathological variables. In 
the previous study, quantification of TLR expression levels relied on both the intensity and percentage of stained 
cells, whereas we only evaluated staining intensity.
TLR7 was previously thought to reduce the viability of gastric cancer cells15. Accordingly, we found that prog-
nosis was better amongst patients with a high TLR7 expression in several subgroups, particularly among those 
with locally advanced disease. Interestingly, we recorded no gastric cancer–related deaths among stage I patients 
with a high TLR7 expression. Although patients with stage I disease typically enjoy a good overall prognosis, it is 
Figure 3. Gastric cancer patients’ disease-specific survival by subgroup according to the Kaplan–Meier 
method, with p values for significance based on the log-rank test. A high versus a low TLR5 expression amongst 
patients with (A) stage II disease, (B) an intestinal-, and (C) a diffuse-type cancer. A high versus a low TLR7 
expression amongst patients with (D) stage I and (E) stage III disease. (F) A high versus a low TLR9 expression 
amongst patients with stage II disease.
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very surprising that no deaths due to gastric cancer were recorded. Unfortunately, the number of patients in this 
subgroup was too small to draw definitive conclusions; our results, however, encourage further study of TLR7 
expression in early-stage gastric cancer.
TLR-related therapy, particularly TLR agonists, capable of activating the immune system against cancer have 
been broadly studied in several malignancies18,19. The administration of a TLR7 agonist, imiquimod, increases the 
expression of TLR7 in gastric cancer cells and reduces their viability15. Whether imiquimod has direct cytotoxic 
effects or if acting via the modulation of inflammatory cell activity remain incompletely understood since numer-
ous different pathways are involved. In vitro studies of imiquimod on colon and basal cell carcinoma cells suggest 
that it can directly induce cell death20,21.
In addition, gastric cancer predisposing H. pylori infection induces polymorphous TLR expression in the gas-
tric mucosa, since TLRs are essential for immunity against it22–25. Genetic variations of TLR1, TLR5, and TLR9 
may contribute to the malignant transformation of the gastric mucosa by altering the immune response to H. 
pylori16,26,27. On the other hand, a TLR2 polymorphism was recently shown to function as a potential prognostic 
biomarker in gastric cancer patients independent of H. pylori infection status, suggesting that gastric carcinogen-
esis affecting signalling pathways does not merely limit to crosstalk with H. pylori28. Conversely, we identified no 
TLR2 protein expression that functioned as a prognostic biomarker in gastric cancer patients, although the results 
related to protein expression and gene polymorphism analyses are not directly comparable. Unfortunately, in our 
retrospective study, patients’ serum antibody levels against H. pylori were unavailable and the H. pylori infection 
status from the archived tissue samples was impossible to reliably determine.
The strengths of this study include the large patient cohort with precise and reliable follow-up information 
and the uniformity of laboratory methods used to determine the expression levels of TLRs. Yet, the single-centre 
setting introduces a bias and limits the generalisability of our results. Additional studies on other well-defined 
patient cohorts are needed in order to validate our results. Furthermore, in addition to H. pylori infection status, 
the limitations of this study include the lack of information for certain other well-known risk factors in our gastric 
cancer cases, such as venous and perineural invasion, lymphatic emboli, and the tumour subsite. Accessing details 
regarding each of these factors in a retrospective manner may potentially introduce inaccuracies and, thus, we 
did not include them in our analyses. Automated digital scoring systems have proved beneficial in improving the 
reproducibility of evaluating the visual density of immunohistochemically stained samples29. Some automated 
digital systems can already identify individual cells; however, the available systems cannot yet reliably interpret 
the cells’ morphological features, and, thus, identify malignant cells from the stroma30–32. Studying heterogene-
ous tissues, reliably identifying neoplastic cells from non-neoplastic cells remain essential in order to produce 
High TLR5 High TLR7 High TLR9
HR 95% CI p value HR 95% CI p value HR 95% CI p value
Age, years
   <67 0.55 0.32–0.95 0.033 1.07 0.67–1.73 0.767 0.90 0.56–1.43 0.648
   ≥67 0.66 0.42–1.02 0.059 0.72 0.47–1.10 0.131 0.69 0.45–1.05 0.086
Gender
   Male 0.68 0.42–1.10 0.114 0.98 0.62–1.56 0.932 0.82 0.52–1.30 0.400
   Female 0.63 0.39–1.02 0.058 0.84 0.54–1.31 0.443 0.87 0.57–1.34 0.534
Stage
   I 0.41 0.05–3.67 0.423 0.03 0.01–97.7 0.392 1.59 0.26–9.63 0.613
   II 0.33 0.13–0.83 0.019 0.79 0.35–1.79 0.572 0.30 0.12–0.76 0.011
   III 0.96 0.60–1.52 0.853 0.60 0.38–0.95 0.029 0.93 0.60–1.44 0.728
   IV 0.97 0.51–1.85 0.923 0.87 0.48–1.56 0.634 1.23 0.71–2.16 0.461
Tumour classification (pT)
   pT1 0.44 0.05–4.23 0.476 N/A 0.34 0.04–3.25 0.348
   pT2 0.72 0.19–2.73 0.629 0.99 0.30–3.24 0.984 1.55 0.46–5.21 0.476
   pT3 0.58 0.33–1.01 0.056 0.93 0.55–1.57 0.798 0.99 0.59–1.66 0.956
   pT4 0.76 0.48–1.19 0.229 0.51 0.32–0.80 0.003 0.86 0.56–1.31 0.470
Lymph node metastasis (pN)
   pN0 0.69 0.31–1.54 0.364 1.66 0.78–3.53 0.190 0.67 0.31–1.47 0.317
   pN1–3 0.69 0.47–1.02 0.062 0.67 0.47–0.96 0.029 0.81 0.57–1.16 0.250
Distant metastasis (pM)
   pM0 0.66 0.44–0.99 0.044 0.82 0.56–1.20 0.307 0.73 0.50–1.06 0.101
   pM1 0.97 0.51–1.85 0.923 0.87 0.48–1.56 0.634 1.23 0.71–2.16 0.461
Laurén classification
   Intestinal 0.58 0.34–0.98 0.043 1.06 0.58–1.96 0.844 0.80 0.44–1.45 0.460
   Diffuse 0.83 0.53–1.31 0.417 1.05 0.69–1.62 0.812 1.06 0.70–1.58 0.794
Table 6. Survival analyses by subgroups, high TLR5, TLR7, and TLR9 expressions compared to low in 313 
gastric cancer patients. Abbreviations: TLR = Toll-like receptor, CI = Confidence interval, HR = Hazard ratio, 
N/A = not available.
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reproducible data. Furthermore, in the context of toll-like receptors, the tumour microenvironment’s immune cell 
toll-like receptor expression limits the application of the digital colourimetric quantification of tissue cores. Thus, 
in this study, digital colourimetric quantification of tissue cores was, unfortunately, not possible.
To conclude, in this study we show, for the first time, that a high TLR5 tissue expression may identify gastric 
cancer patients with a better prognosis, particularly amongst those with a stage II disease or an intestinal-type 
cancer. In a small subgroup of stage I disease, none of the patients with a high TLR7 expression died from gastric 
cancer. In addition, we found that a high expression of TLR1, TLR2, TLR4, TLR5, TLR7, and TLR9 associated 
with an intestinal-type gastric cancer and with a high expression of all other TLRs.
Data Availability
All data and materials are available from the corresponding author upon request.
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